Adjunctive treatment for MDD

Adjunctive treatment for MDD

• A. Clozapine, olanzapine, quetiapine, risperidone
• B. Antagonism in dopaminergic pathways
• C. Depressive episode treatment in bipolar disorder
• D. Short-term management of aggression and/or psychosis-related inappropriate behaviors

Answer: (A)

Augmenting antidepressant therapy with a second-generation antipsychotic is a well-supported approach for major depressive disorder, especially when a patient has not fully responded to antidepressants alone. These antipsychotics can boost mood symptoms, reduce anxiety, and improve overall response when added to ongoing antidepressant treatment. The agents listed—olanzapine, quetiapine, and risperidone—have the strongest and most consistent evidence for use as augmentation in MDD. Clozapine is less commonly used for this purpose due to safety concerns, but it has been explored as augmentation in some treatment-resistant cases. This concept stands in contrast to the other options: one describes a general pharmacologic mechanism of antipsychotics rather than a specific adjunctive strategy for MDD, another points to bipolar depression rather than unipolar MDD, and the last describes short-term management of agitation or psychosis, which does not address augmentation of depressive symptoms.

Augmenting antidepressant therapy with a second-generation antipsychotic is a well-supported approach for major depressive disorder, especially when a patient has not fully responded to antidepressants alone. These antipsychotics can boost mood symptoms, reduce anxiety, and improve overall response when added to ongoing antidepressant treatment. The agents listed—olanzapine, quetiapine, and risperidone—have the strongest and most consistent evidence for use as augmentation in MDD. Clozapine is less commonly used for this purpose due to safety concerns, but it has been explored as augmentation in some treatment-resistant cases. This concept stands in contrast to the other options: one describes a general pharmacologic mechanism of antipsychotics rather than a specific adjunctive strategy for MDD, another points to bipolar depression rather than unipolar MDD, and the last describes short-term management of agitation or psychosis, which does not address augmentation of depressive symptoms.